Xuena Wang

发表

Estimating Treatment Effects for Recurrent Events in the Presence of Rescue Medications: An Application to the Immune Thrombocytopenia Study

J. Ibrahim, D. Zeng, F. Gao, 2018, Statistics in biosciences.

Serum Galectin-3 levels and all-cause and cardiovascular mortality in maintenance hemodialysis patients: a prospective cohort study

Qijun Wu, Zhihong Wang, Shuxin Liu, 2022, BMC Nephrology.

Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP).

M. Sanz, L. Aledort, Xuena Wang, 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost per response analysis of strategies for chronic immune thrombocytopenia.

M. Campioni, R. Zur, K. Cetin, 2018, The American journal of managed care.

Romiplostim or standard of care in patients with immune thrombocytopenia.

B. Chong, F. Rodeghiero, I. Pabinger, 2010, The New England journal of medicine.

Long‐term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials

D. Cines, J. Viallard, A. Giagounidis, 2013, European journal of haematology.

Estimating Treatment Effects for Recurrent Events in the Presence of Rescue Medications: An Application to the Immune Thrombocytopenia Study

J. Ibrahim, D. Zeng, Helen Wei, 2016, Statistics in Biosciences.

A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.

S. Aggarwal, J. Gray, A. Spira, 2021, Lung cancer.

Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥65 years with immune thrombocytopenia

Y. Tomiyama, L. Aledort, J. Wasser, 2015, Annals of Hematology.

Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia

B. Chong, F. Rodeghiero, J. Franklin, 2016, Annals of Hematology.

Health‐related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care

A. Giagounidis, D. Kuter, R. Deuson, 2012, American journal of hematology.

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia

M. Steurer, D. Cines, B. Chong, 2017, Haematologica.

Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim

J. Wasser, B. Godeau, R. Lyons, 2015, International Journal of Hematology.

Results From a Phase IV Open-Label Study Evaluating Changes In Bone Marrow Morphology In Adult Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim: Analysis Of The 1- and 2-Year Romiplostim Cohorts

B. Chong, F. Rodeghiero, I. Pabinger, 2013 .

Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP)

J. Viallard, I. Pabinger, J. Wasser, 2011 .

The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.

B. Chong, F. Rodeghiero, I. Pabinger, 2010 .

Home Administration of Romiplostim by Patients with Chronic Immune Thrombocytopenia (ITP).

R. Lyons, R. Mandanas, R. Boccia, 2009 .

Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim†

J. Bussel, Xuena Wang, M. Eisen, 2016, Hematology.

Final Results from a Phase 4 Open-Label 3-Year Study Evaluating Changes in Bone Marrow (Bm) Morphology in Adult Immune Thrombocytopenia (ITP) Patients (Pts) Receiving the Thrombopoietin Mimetic Romiplostim

B. Chong, F. Rodeghiero, I. Pabinger, 2014 .

Case Studies Of Remission In Adults With Immune Thrombocytopenia (ITP) Following Cessation Of Treatment With The TPO Receptor Agonist Romiplostim

Xuena Wang, M. Eisen, 2013 .

Effects of cisatracurium in combination with ventilation on inflammatory factors and immune variations in sepsis rats

Xuena Wang, Tongyun He, Jianmei Tao, 2018, Experimental and therapeutic medicine.

Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.

B. Chong, F. Rodeghiero, I. Pabinger, 2009 .